GigaGen CEO David Johnson to Present at 2017 Antibody Engineering & Therapeutics Meeting
Dec 14, 2017, 07:00 ET
SOUTH SAN FRANCISCO, Calif., Dec. 14, 2017 /PRNewswire/ -- GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that David Johnson, Ph.D., chief executive officer, will present at the 2017 Antibody Engineering & Therapeutics Meeting. Dr. Johnson's presentation will take place at 3:30 p.m. PST on December 15, 2017, at the Manchester Grand Hyatt in San Diego, Calif.
Dr. Johnson's presentation titled, "Discovery of Potent Anti-Tumor TCRs in Recombinant TCR Libraries Generated from Tumor Infiltrating Lymphocytes," will discuss the use of GigaGen's proprietary Surge technology in T cell receptor (TCR) work, which was spun out into a new cellular therapy company, GigaMune, Inc., in summer 2017.
"We are excited by the potential of Surge, our high-throughput single cell droplet microfluidic technology, to help us uncover the role of the T cell repertoire in cancer, infectious diseases and autoimmunity. This unique insight into immune dysregulation is enabled by quickly characterizing T cells within complex immune systems. Our research on T cells thus far has demonstrated the power of Surge to generate a robust portfolio of rare high-potential clinical TCR candidates against novel targets," said Dr. Johnson. "We are particularly encouraged by our latest data on anti-cancer TCRs, which have the potential to form the basis of novel cell therapies."
GigaGen is a privately-held, preclinical biopharmaceutical company developing novel antibody therapies to treat diseases of immune dysregulation. GigaGen's deep understanding of immune dysregulation is enabled by industry-leading technology that quickly captures the genetic makeup of entire immune repertoires to analyze B cells at a rate of millions per hour, while simultaneously identifying their antigen and protein binders. GigaGen has a robust internal pipeline consisting of novel antibodies against immuno-oncology targets, in addition to the first recombinant intravenous immunoglobulin (IVIG) for patients with immune deficiency. For more information visit www.GigaGen.com.
SOURCE GigaGen Inc.
Share this article